PD-(L)1 x VEGF bispecifics prove a big draw.
ApexOnco Front Page
Recent articles
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
Could a new ADC project distract attention away from evorpacept?
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
